featured
Overall Survival With Daratumumab, Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Overall Survival With Daratumumab, Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma (ALCYONE): A Randomised, Open-Label, Phase 3 Trial
Lancet 2019 Dec 10;[EPub Ahead of Print], MV Mateos, M Cavo, J Blade, MA Dimopoulos, K Suzuki, A Jakubowiak, S Knop, C Doyen, P Lucio, Z Nagy, L Pour, M Cook, S Grosicki, A Crepaldi, AM Liberati, P Campbell, T Shelekhova, SS Yoon, G Iosava, T Fujisaki, M Garg, M Krevvata, Y Chen, J Wang, A Kudva, J Ukropec, S Wroblewski, M Qi, R Kobos, J San-MiguelFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.